Remus Pharmaceuticals share price
NSE: REMUSPharmaceuticals & Biotechnology
Remus Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2023 · Issue price ₹1,229
Last close ₹873.80down ₹0.55 (0.06%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹874.35.
29 Oct: open ₹856.20, high ₹881.05, low ₹855.00
52-week range of traded prices to 29 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results, dividend and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹1,030 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.84
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,60073.1% delivered
Results
Consolidated; ₹ crore.Remus Pharmaceuticals half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +37.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹453 Crup 13.30%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹25 Crup 13.85%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.4%
Revenue by half year
Peak revenue ₹453 Cr, half year to Mar 2026; lowest ₹29 Cr, half year to Sep 2023
Net profit by half year, a loss in red
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 29 | 183 | 273 | 348 | 400 | 453 |
| Net profit | 6 | 16 | 14 | 21 | 22 | 25 |
| Net margin | 19.4% | 8.7% | 5.1% | 5.9% | 5.4% | 5.4% |
Consolidated. The 6 half years from Sep 2023, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹854 Crup 37.60%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹46 Crup 20.17%
- Net margin
- 5.4%
Revenue by year
Peak revenue ₹854 Cr, year to Mar 2026; lowest ₹212 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 212 | 620 | 854 |
| Net profit | 22 | 38 | 46 |
| Net margin | 10.1% | 6.2% | 5.4% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history.Remus Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 78% of 236 trading days over the last year.
LowestHighest
Its median24.67Industry median28.38
Price to book
At or below today's level on 74% of 243 trading days over the last year.
LowestHighest
Its median2.67Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 70% of 739 trading days over the last 3 years.
LowestHighest
Its median0.10%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −43.8% | +27.2% | −55.9% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Remus Pharmaceuticals insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group5 purchases, 0 sales₹0.38 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹0.38 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Remus Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Remus Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Fermenta BiotechFERMENTA | 1,292 | – | 3.18 | −3.2% | – | – | 13.5% | 0.85% |
 KopranKOPRAN | 1,218 | 48.75 | 2.30 | +12.0% | −28.4% | 4.8% | 6.2% | 1.19% |
 Bafna PharmaceuticalsBAFNAPH | 1,081 | 138.85 | 11.24 | −3.1% | −5.8% | 8.6% | 4.0% | 0.00% |
 Bajaj HealthcareBAJAJHCARE | 1,053 | 51.09 | 1.89 | +14.2% | −55.0% | 4.0% | 10.2% | 0.48% |
 Lincoln PharmaceuticalsLINCOLN | 1,021 | 10.54 | 1.26 | +14.2% | +21.1% | 12.7% | 10.4% | 0.35% |
 Sigachi IndustriesSIGACHI | 1,016 | 40.09 | 1.95 | −9.6% | – | 4.5% | 4.3% | 0.38% |
 Themis MedicareTHEMISMED | 898 | 22.47 | 2.25 | −12.8% | – | 10.0% | −10.5% | 0.51% |
 Shree Ganesh RemediesSGRL | 821 | 53.21 | 5.04 | −8.8% | −29.4% | 10.0% | 10.6% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Remus Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.00 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 22 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.50 |
| 14 Nov 2025 | Interim | ₹0.50 |
| 18 Sep 2025 | Final | ₹0.50 |
| 19 Nov 2024 | Interim | ₹1.00 |
| 2 May 2024 | Interim | ₹4.00 |
| 27 Oct 2023 | Interim | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Remus Pharmaceuticals announcements
Oct 2026
28 Oct · Analysts
7 Oct · Meeting
Sep 2026
29 Sep · Meeting
7 Sep · Corporate action
Remus Pharmaceuticals share price by year
Each calendar year to 2025.Remus Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 702.20 | −43.8% | 1,256.75 | 628.70 |
| 2024 | 1,248.75 | +30.5% | 1,362.28 | 610.74 |
| 2023 | 956.69 | – | 956.69 | 224.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 29 May 2023.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 885.40 | 885.40 | 855.20 | 874.35 | 872.49 | 3,500 | 77.1% |
| 27 Oct 2026 | 900.00 | 905.00 | 860.00 | 880.45 | 885.47 | 4,600 | 84.8% |
| 26 Oct 2026 | 905.00 | 905.00 | 890.10 | 892.30 | 892.31 | 1,600 | 93.8% |
| 23 Oct 2026 | 881.00 | 890.00 | 860.00 | 880.60 | 874.39 | 2,800 | 85.7% |
| 22 Oct 2026 | 911.00 | 935.00 | 897.00 | 901.20 | 912.75 | 3,100 | 87.1% |
| 21 Oct 2026 | 953.05 | 974.95 | 906.00 | 915.75 | 933.22 | 6,500 | 76.9% |
| 19 Oct 2026 | 1,000.00 | 1,000.00 | 972.90 | 984.50 | 985.74 | 3,400 | 64.7% |
| 16 Oct 2026 | 1,006.00 | 1,016.00 | 1,000.00 | 1,002.00 | 1,004.36 | 3,700 | 75.7% |
| 15 Oct 2026 | 1,014.00 | 1,039.00 | 990.00 | 1,011.55 | 1,021.43 | 13,100 | 55.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 4 Jul 2025 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 6 Jun 2024 | Bonus | 0.2500 | Holders received 3 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- REMUS
- ISIN
- INE0O5T01011
- Industry
- Pharmaceuticals & Biotechnology